Roflumilast tablets (Roflumilast) - How much should DALIRESP take at one time?

Roflumilast - The recommended maintenance dose of DALIRESP is 500 micrograms (mcg) once daily, which can be taken with or without food. This drug is mainly used for adult patients with chronic obstructive pulmonary disease (COPD; COPD) who have chronic bronchitis and repeated acute exacerbations. Although the standard treatment dose is 500mcg daily, in clinical practice, in order to help some patients better tolerate initial side effects, such as nausea, weight loss, diarrhea, etc., doctors may recommend that patients start treatment with a low dose of 250mcg once a day for about 4 weeks, and then increase to the standard dose of 500mcg once a day. This escalating dose approach does not provide the full efficacy needed for treatment, but studies have shown that it can effectively reduce the risk of patients discontinuing treatment due to side effects early on.

It should be noted that 250mcg once a day is not an effective therapeutic dose, and long-term use of this dose cannot achieve the anti-inflammatory effect of roflumilast. Therefore, patients should gradually transition to a maintenance dose of 500mcg under the guidance of a doctor. When taking medicine, try to take it at the same time every day to maintain a stable drug concentration and improve the therapeutic effect. Roflumilast is contraindicated in patients with moderately or severely impaired hepatic function, and risks and benefits need to be carefully assessed in patients with mildly abnormal hepatic function or underweight.

In addition, roflumilast is not used to relieve acute exacerbations, nor can it replace conventional COPD drugs such as bronchodilators or glucocorticoidsIt is used as an auxiliary drug for long-term control, especially for patients with frequent acute exacerbations. To ensure efficacy and safety, patients should receive regular follow-up visits from doctors during use and monitor possible side effects such as weight changes and mental status. If persistent discomfort occurs, you should seek medical advice promptly to evaluate whether to adjust the dose or terminate the medication.

References:https://www.ema.europa.eu/en/medicines/human/EPAR/daxas